Tesamorelin's effect on tesamorelin metabolic syndrome parameters follows a logical chain: Less visceral fat lower portal free fatty acid load reduced hepatic insulin resistance Improved GH/IGF-1 better systemic insulin sensitivity Reduced VAT lower inflammatory cytokine output improved lipid profile Lower triglycerides reduced cardiometabolic risk This is why tesamorelin interests metabolic clinicians beyond its approved HIV indication
Zhang X, Selvaraju K, Saei AA, DArcy P, Zubarev RA, Arner ES, Linder S (2019) Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug
Enter Semaglutide, a groundbreaking injectable for weight loss thats giving traditional dieting a serious run for its money
Is retatrutide a "GLP-3"
Gradient: 550% B over 20 minutes
However, it's not sustainable long-term because you won't meet your protein, fiber, and healthy fat needs